AbbVie Reports First-Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Abbvie (ABBV) PT Raised to $129 at BMO Capital
May 3, 2021 7:31 AM EDTBMO Capital analyst Gary Nachman raised the price target on Abbvie (NYSE: ABBV) to $129.00 (from $127.00) while maintaining an Outperform rating.
The analyst commented, "1Q was high quality with solid top-line beat (mainly from Aesthetics and Immunology) dropping to bottom line, and improved diversification of... More
AbbVie (ABBV) Tops Q1 EPS by 12c, Offers FY Guidance
April 30, 2021 7:43 AM EDTAbbVie (NYSE: ABBV) reported Q1 EPS of $2.95, $0.12 better than the analyst estimate of $2.83. Revenue for the quarter came in at $12.94 billion versus the consensus estimate of $12.76 billion.
GUIDANCE:
AbbVie sees FY2021 EPS of $12.37-$12.57, versus the consensus of... More
